Last reviewed · How we verify
SHR-2005
At a glance
| Generic name | SHR-2005 |
|---|---|
| Sponsor | Shanghai Hengrui Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase I Clinical Study of SHR-2005 Intravesical Instillation in the Treatment of Intermediate and High-risk Non-muscle Invasive Bladder Cancer (NMIBC) (PHASE1)
- SHR-1501 Combined With SHR-2005 for High-Risk Non-Muscle Invasive Bladder Cancer Which is Not Completely Resectable by TURBt (PHASE1, PHASE2)
- Mesh and Mesh Fixation in Laparoscopic Groin Hernia Surgery
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SHR-2005 CI brief — competitive landscape report
- SHR-2005 updates RSS · CI watch RSS
- Shanghai Hengrui Pharmaceutical Co., Ltd. portfolio CI